Moleculin Biotech, Inc.

What they do

Moleculin is a late-stage pharmaceutical development company evaluating Annamycin (naxtarubicin), which it describes as a next-generation anthracycline, in combination with cytarabine for relapsed/refractory acute myeloid leukemia (AML). The lead program is the pivotal Phase 2/3 MIRACLE trial. The company also holds two additional portfolios of technologies for hard-to-treat cancers and viruses, with clinical and preclinical research funded by investigators at academic institutions. Its three core technologies are based substantially on discoveries made at, in conjunction with, or licensed from the University of Texas MD Anderson Cancer Center.

Revenue drivers

• Annamycin / MIRACLE program — Lead candidate in a pivotal Phase 2/3 trial in combination with cytarabine for relapsed/refractory AML; the company's central development asset and the focus of its disclosed milestones. No product revenue has been recorded.
• Additional cancer and virus portfolios — Two additional technology portfolios for hard-to-treat cancers and viruses, with one ongoing investigator-initiated trial, one planned, and active preclinical testing. These are earlier-stage than Annamycin.
• MD Anderson-derived licensing — All three core technologies are based substantially on discoveries made at, made in conjunction with, and/or licensed from MD Anderson; the company's pipeline depends on these licenses and sponsored research relationships.

Recent performance

Moleculin reported no revenue for the quarters ended September 30, 2025, December 31, 2025, March 31, 2026, and June 30, 2026, consistent with its clinical-stage status. For the second quarter of 2026, the company reported positive preliminary unblinded results from the first 45 patients in Part A of the MIRACLE trial: complete remission reached 43% and 36% in the two Annamycin cohorts versus 12% for control, and composite complete remission reached 50% and 57% versus 29% for control. As of June 30, 2026, total assets were $21.1 million, total liabilities $9.5 million, shareholder equity $11.6 million, and cash and equivalents $7.3 million. The company said cash on hand plus $9.3 million raised after quarter-end is expected to fund operations into the first quarter of 2027. Operating cash flow was negative $22.7 million for 2025.

Strategy

The company is advancing the MIRACLE trial toward planned 90-patient enrollment in September 2026, with an unblinded readout expected in the December 2026 to February 2027 timeframe. Those data are expected to support selection of the optimal Annamycin dose and planned initiation of Part B in the first half of 2027. Moleculin is also funding earlier-stage work across two additional portfolios for hard-to-treat cancers and viruses through investigator-sponsored research. The company states it must raise additional funding to commence or continue trials and fund operations, and it has flagged regaining and maintaining Nasdaq Capital Market listing compliance as an objective.

Risks

• No revenue and negative cash flow — The company has recorded no revenue in recent quarters and used $22.7 million in operating cash flow in 2025, funding itself through financings.
• Clinical trial uncertainty — The pivotal MIRACLE outcome depends on Part A and Part B results combined; the interim finding of higher complete remission rates in 45 patients is preliminary and may not be replicated in the full trial.
• Funding runway — Management expects cash on hand plus $9.3 million raised after quarter-end to fund operations only into the first quarter of 2027, requiring further capital before key data readouts.
• Dependence on MD Anderson relationships — Each core technology is based on discoveries licensed from or made with MD Anderson, so maintaining those licenses and sponsored research agreements is material to the pipeline.

Outlook

Management says MIRACLE enrollment remains on track to reach the 90-patient milestone in September 2026, with the unblinded efficacy readout in the December 2026 to February 2027 timeframe. It expects those data to support optimal dose selection and planned initiation of Part B in the first half of 2027. The company also expects its current cash plus post-quarter financing to fund planned operations into the first quarter of 2027.